Feb 13th 2013 - Edison Investment Research today published a report on quickview entitled "Pancreatic Potential". In summary, the report says:
Subset analysis data presented at ASCO-GI highlight the potential of masitinib in pancreatic cancer. In particular, the improvement in overall survival of six months in patients with a specific biomarker compares very favourably with other gemcitabine combinations. A decision on European conditional approval in both this and the GIST indication is due in Q4/13 and is likely to be a key value driver for the shares.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
